Technical Data
T9160-41F
Tumor Necrosis Factor beta, Recombinant, Human (TNF-beta, TNFb, Lymphotoxin-alpha, LT-alpha, LTA, LT, Tumor Necrosis Factor Ligand Superfamily Member 1, TNFSF1)
5ug
|
Technical Data |
|
T9160-41F |
Tumor Necrosis Factor beta, Recombinant, Human (TNF-beta, TNFb, Lymphotoxin-alpha, LT-alpha, LTA, LT, Tumor Necrosis Factor Ligand Superfamily Member 1, TNFSF1) |
5ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Source: Recombinant corresponding to 171aa of human Tumor Necrosis Factor-beta (Lymphotoxin) expressed in E. coli is a non-glycosylated, polypeptide chain. Molecular Weight: ~18.6kD Biological Activity: The ED50 as determined by the cytolysis of mouse L929 cells in the presence of Actinomycin D is less then 0.05ng/ml, corresponding to a Specific Activity of 2x10 IU/mg. Dimmers and Aggregates: 1% (SDS-PAGE) Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 1.082 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of TNF-beta as a Reference Standard. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: ~18.6kD |
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug) Concentration: Not determined Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Association of TNF-alpha and TNF-beta gene polymorphism with steroid receptor expression in breast cancer patients. Pathol Oncol Res 2005;11(2):99-102. 2. Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett 2005 Jun 1;223(1):113-9. 3. Genetic polymorphisms of TGF-beta1 & TNF-beta and breast cancer risk. Breast Cancer Res Treat 2005 Mar;90(2):149-55. 4. TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens 2005 Jan;65(1):93-100. 5. Polymorphisms within the genes encoding TNF-alpha and TNF-beta associate with the incidence of post-transplant complications in r ecipients of allogeneic hematopoietic stem cell transplants. Arch Immunol Ther Exp (Warsz) 2004 Jul-Aug;52(4):240-9. 6. Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism. Hum Immunol 2004 Jun;65(6):622-31.
|
||